Minerva Neurosciences, Inc.

Based in Burlington, Massachusetts, Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases. The company's lead product candidate is roluperidone, which is being evaluated for treating negative symptoms in schizophrenia patients. Minerva also holds exclusive development and commercialization rights to MIN-301, a soluble recombinant form of Neuregulin-1b1 protein, for potential use in Parkinson's disease and other neurodegenerative disorders. Both candidates remain in clinical development stages.

The company operates with a small team of eight full-time employees and generates revenue primarily through research and development activities. As a pre-commercial clinical-stage entity, Minerva has not yet brought any products to market and does not maintain traditional business segments. The company's operations are centered on advancing its pipeline candidates through clinical trials and regulatory processes. Minerva was incorporated in Massachusetts in 2007 and is listed on the Nasdaq exchange.